STXBP1 and Encephalopathy: Future studies will focus on derivatization, to further enhance efficacy and improve pharmacokinetics across the blood–brain barrier, as well as on testing of these compounds in a hemizygous mouse model of disease, which mimics human nonsense, frameshift, and deletion mutations and has a phenotype that overlaps with symptoms of Munc18‐1 encephalopathies (Chen et al, 2020).